AKT1 can restrict the invasive capacity of HNC cells through the EGFR-PI3K-AKT-mTOR signaling axis (Brolih et al., 2018) and was involved in acquired cetuximab resistant HNSCC (Zaryouh et al., 2021). The gene discussed is AKT1; the disease is head and neck squamous cell carcinoma.